Tscan therapeutics announces fda clearance of three investigational new drug applications for the treatment of solid tumors

Primary ind for solid tumor program, t-plex, supports simultaneous use of multiple tcrs to create customized, multiplexed tcr-t cell therapies based on target and hla expression

TCRX Ratings Summary

TCRX Quant Ranking